K Pharmaceuticals Unveils the First Personalized Xerostomia Protocol (PXP) to Address the Growing Dry Mouth Crisis

K Pharmaceuticals, manufacturer of Aquoral Protective Oral Spray (aquoralspray.com/dashboard) is proud to introduce the first ever in-office Personalized Xerostomia Protocol (PXP) for Dental Professionals. This initiative aims to address the growing dry mouth crisis and its related systemic implications. Once considered mostly a condition of the elderly or those with disease-related xerostomia, dry mouth prevalence has increased to one in four individuals. This increase is attributed to side effects of most medications (including trending weight loss drugs), use of CPAP machines, and the rising use of marijuana.

Created in partnership with Melissa Turner, BASDH, RDHEP, EFDA, a leading Registered Dental Hygienist and Dental Brand Strategist, the PXP tool marks a significant step toward establishing comprehensive global xerostomia guidelines. It is designed for use with every patient at every appointment, offering a straightforward method to identify and educate patients on dry mouth symptoms, outline treatment guidelines, and adapt and re-evaluate therapy based on evolving health needs.

“Xerostomia has become a silent pandemic that can be detrimental to our patients’ systemic health, often diminishing their quality of life,” stated Melissa Turner. “Ironically, many individuals suffering from dry mouth remain unaware of their condition. The PXP seeks to heighten awareness among dental and medical providers and patients, enabling us to propel the conversation forward and together stand up for xerostomia relief!”

Aquoral, a patented, prescription-strength dry mouth relief spray, has been clinically proven to offer lasting protection of oral tissues. Its patented lipid-based formulation creates a protective barrier on the oral mucosa that remains intact after eating or drinking, making it an excellent complement to existing xerostomia therapies.

Bennett Blakeman, CEO of K Pharmaceuticals, commented: “Patients in both dental and medical practices have suffered too long without an effective solution. Many have described Aquoral as a transformative product, which inspired the development of our new PXP. Our mission is to ensure communities no longer have to suffer from this preventable condition or its often detrimental systemic effects.”

K Pharmaceuticals is honored to work with dental and medical schools as well as leading professional and patient advocacy organizations, including the American Academy of Oral Medicine (AAOM), American Dental Hygienists’ Association (ADHA), Mommy Dentists in Business (MDIB), Support for People with Oral, Head and Neck Cancer (SPOHNC), Thyroid, Head and Neck Cancer Foundation (THANC), National Foundation of Swallowing Disorders (NFOSD), Head and Neck Cancer Alliance (HNCA), Sjogren’s Foundation, and Thyroid Cancer Survivors’’ Association (ThyCa).

To learn more, visit our website to see our conference schedule and experience the product firsthand at the following upcoming events: aquoralspray.com/conferences

K Pharmaceuticals is committed to ongoing education about xerostomia and offers several free continuing education programs for CE credit. Register and access these programs here: aquoralspray.com/programs

About K Pharmaceuticals - Founded in 2022, K Pharmaceuticals is a privately held pharmaceutical company founded by passionate individuals who are dedicated to making innovative medications more accessible to patients. Aquoral is the perfect first product for K Pharmaceuticals to bring back to market. Undervalued by its previous owners, it brings tremendous benefit to its patients based on its technology and differentiating factors.

Contact Information

Bennett Blakeman

CEO

K Pharmaceuticals

(1) 630-319-0778

bblakeman@kpharmaceutical.com